1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) News

INCY

Incyte Corporation

62,37
-0,17 (-0,27%)
Upgrade auf Real-Time
Name Symbol Markt Aktientyp
Incyte Corporation INCY NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,17 -0,27% 62,37 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
62,36 62,18 62,91 62,37 62,54
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
26.5.202309:38BWDonnées du portefeuille d'oncologie d'Incyte acceptées pour..
26.5.202309:05BWDaten aus dem Onkologie-Portfolio von Incyte werden beim..
25.5.202323:01BWData from Across Incyte’s Oncology Portfolio Accepted for..
23.5.202314:00BWIncyte to Present at Upcoming Investor Conferences
08.5.202323:22EDGARCurrent Report Filing (8-k)
08.5.202314:30BWIncyte Strengthens Research & Development Efforts Appointing..
02.5.202322:04EDGARQuarterly Report (10-q)
02.5.202313:00BWIncyte Reports 2023 First Quarter Financial Results and..
01.5.202321:00BWIncyte Announces Results from SCRATCH-AD Trial Demonstrating..
28.4.202314:04EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
28.4.202314:02EDGARAnnual Report to Security Holders (ars)
28.4.202314:02EDGARProxy Statement (definitive) (def 14a)
21.4.202317:45BWIncyte annonce l'approbation de la Commission européenne..
21.4.202306:28BWIncyte meldet EU-Zulassung für Opzelura® (Ruxolitinib) Creme..
20.4.202316:21BWIncyte Announces European Commission Approval of Opzelura®..
18.4.202314:00BWIncyte to Present at Upcoming Investor Conferences
17.4.202313:37BWAprès cinq ans, MorphoSys et Incyte annoncent les résultats..
16.4.202321:01BWMorphoSys and Incyte Announce Five-Year Results of L-MIND..
11.4.202314:00BWIncyte to Report First Quarter Financial Results
04.4.202322:01EDGARStatement of Changes in Beneficial Ownership (4)
04.4.202322:01EDGARStatement of Changes in Beneficial Ownership (4)
28.3.202313:53BWインサイト、「ペマジール®」（ペミガチニブ）が骨髄／リンパ性腫瘍（MLN）患者の治療薬として日本で承認されたと発表
27.3.202316:36BWIncyte annonce l'autorisation du Pemazyre® (pemigatinib) au..
27.3.202313:11BWIncyte gibt japanische Zulassung von Pemazyre® (Pemigatinib)..
27.3.202308:00BWIncyte Announces Japanese Approval of Pemazyre®..
24.3.202312:25BWIncyte fournit une mise à jour réglementaire sur les..
24.3.202312:22BWIncyte legt Aktualisierung zum regulatorischen Stand von..
24.3.202311:39DJNFDA Rejects Incyte's Bid for Once-Daily Jakafi Approval
24.3.202305:23BWIncyte meldet FDA-Zulassung für Zynyz™ (Retifanlimab-dlwr)..
24.3.202301:55BWIncyte Provides Regulatory Update on Ruxolitinib..
23.3.202306:48BWIncyte annonce l'approbation de la FDA pour Zynyz™..
22.3.202319:19DJNIncyte Gets FDA Approval of Zynyz, Triggers Milestone..
22.3.202318:14BWIncyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr)..
18.3.202320:40BWIncyte Announces Data from Phase 2b Study Evaluating..
18.3.202315:40BWIncyte Announces Long-Term Extension Data from Phase 3..
15.3.202321:11EDGARAmended Statement of Beneficial Ownership (sc 13d/a)
15.3.202321:04EDGARStatement of Changes in Beneficial Ownership (4)
14.3.202323:30BWIncyte Announces Data from Across its Oncology Portfolio..
07.3.202312:30PRNUSCaris Life Sciences and Incyte Enter Into Broad Precision..
07.3.202309:05BWMehrere Abstracts aus dem wachsenden Dermatologie-Portfolio..
07.3.202303:46BWPlusieurs résumés de la gamme grandissante de produits..
06.3.202318:23BWMultiple Abstracts from Incyte’s Growing Dermatology..
03.3.202322:35BWIncyte Provides Update on Interim Analysis of Phase 3..
25.2.202302:01BWIncyte meldet positive CHMP-Stellungnahme für..
24.2.202320:48BWIncyte annonce l'avis favorable du CHMP pour la crème..
24.2.202313:07BWIncyte Announces Positive CHMP Opinion for Ruxolitinib Cream..
21.2.202322:01EDGARStatement of Changes in Beneficial Ownership (4)
16.2.202314:00BWIncyte to Present at Upcoming Investor Conference
15.2.202322:01EDGARStatement of Changes in Beneficial Ownership (4)
11.2.202311:36BWIncyte gibt 52-Wochen-Ergebnisse der Phase-II-Studie mit..
Kürzlich von Ihnen besucht
NASDAQ
INCY
Incyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Melden Sie sich bei ADVFN an
Jetzt registrieren

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

Support: +44 (0) 203 8794 460 | support@advfn.de

V: D: 20230606 00:24:10